Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986165 in Moderate to Severe Crohn's Disease
CTR20192321Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deucravacitinib in Crohn's disease, sponsored by Bristol Myers Squibb. Started Nov 2019; status: terminated.
02
Drugs
deucravacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20192321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192321.